Using a computer-generated randomisation sequence , we randomly allocated antiretroviral-naive adult patients with HIV-1 and tuberculosis ( aged 18 years with a plasma HIV RNA concentration of > 1000 copies per mL ) to receive raltegravir 400 mg twice a day , raltegravir 800 mg twice daily , or efavirenz 600 mg once daily plus tenofovir and lamivudine ( 1:1:1 ; stratified by country ) .